Bristol-Myers Squibb Co and Daiichi Sankyo said they would collaborate on a clinical trial to evaluate a combination of Bristol-Myers' immuno-oncology drug, Opdivo, with the Japanese company's experimental drug in patients with breast and bladder cancers.

The companies said the study in patients with HER2-expressing advanced breast and bladder cancer is expected to begin enrollment in the first quarter of 2018.

This article was provided by Reuters.